Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 764 of 5804
-
Experimental vaccine aims to boost immune attack on Hard-to-Treat cancers
Disease control OngoingRef: Protocol Version 9.1 05 December 2024. NOUS-209-01 is a multicenter, open-label, multiple cohorts, clinical study, designed to evaluate safety, tolerability, and immunogenicity, and to detect any preliminary evidence of anti-tumor activity of Nous-209 genetic polyvalent vacc…
Phase: PHASE1, PHASE2 • Sponsor: Nouscom SRL • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
New light therapy aims to halt cornea disease and save sight
Disease control Recruiting nowTo evaluate the safety and effectiveness of the PXL Platinum 330 system for performing corneal cross-linking (CXL) for the treatment of ectatic disorders.
Phase: PHASE2 • Sponsor: Goodman Eye Center • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
150,000 people tracked to see if At-Home stool test can slash colon cancer deaths
Diagnosis OngoingThe purpose of this study is to gather information about the long term health of people who have been prescribed the Cologuard test, which is used for colorectal cancer (CRC) screening.
Sponsor: Exact Sciences Corporation • Aim: Diagnosis
Last updated Jun 27, 2026 07:53 UTC
-
New hope for teens with MS: drug trial aims to cut relapses
Disease control OngoingThis study will evaluate the safety, tolerability, and descriptive efficacy of BIIB017 in pediatric participants with relapsing-remitting multiple sclerosis (RRMS) and to assess the pharmacokinetics (PK) of BIIB017 in pediatric participants with RRMS in Part 1. In Part 2, the stu…
Phase: PHASE3 • Sponsor: Biogen • Aim: Disease control
Last updated Jun 26, 2026 15:45 UTC
-
Gene-Guided drugs aim to shrink brain tumors
Disease control OngoingThis phase II trial studies how well genetic testing works in guiding treatment for patients with solid tumors that have spread to the brain. Several genes have been found to be altered or mutated in brain metastases such as NTRK, ROS1, CDK, PI3K, or KRAS G12C. Medications that t…
Phase: PHASE2 • Sponsor: Alliance for Clinical Trials in Oncology • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
Heated chemo plus immunotherapy shows promise for tough ovarian cancers
Disease control CompletedSpread pattern, the lack of alternative treatments, and emerging data on the activity of anti-Programmed death ligand 1 (PDL1) targeted checkpoint inhibitor therapy in gynecological cancers provide the rationale for this investigation. Surgery and Hyperthermic Intraperitoneal Ch…
Phase: PHASE1, PHASE2 • Sponsor: Hospices Civils de Lyon • Aim: Disease control
Last updated Jun 27, 2026 08:05 UTC
-
New hope for kids with eye inflammation: baricitinib trial shows promise
Disease control OngoingThe reason for this study is to see if the study drug baricitinib given orally is safe and effective in participants with active juvenile idiopathic arthritis (JIA)-associated uveitis or chronic anterior antinuclear antibody-positive uveitis from 2 years to less than 18 years old…
Phase: PHASE3 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New hope for sickle cell patients: drug cuts painful erections
Disease control CompletedThe goal of the study was to evaluate the efficacy and safety of crizanlizumab in sickle cell disease (SCD) patients with priapism.
Phase: PHASE2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
New hope for lymphoma patients who Can't tolerate standard drugs
Disease control CompletedThe primary objective of this study is to evaluate the safety of zanubrutinib (also known as BGB-3111) in chronic lymphocytic leukemia/small lymphocytic lymphoma, Waldenström macroglobulinemia, mantle cell lymphoma, or marginal zone lymphoma patients who have become intolerant of…
Phase: PHASE2 • Sponsor: BeiGene • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
New drug cocktail aims to control rare blood cancer without chemo
Disease control OngoingThis is a multi-arm phase 2 study to evaluate the preliminary evidence of efficacy and safety of the combination of acalabrutinib, lenalidomide and rituximab (ALR) and acalabrutinib, lenalidomide and obinutuzumab (ALO) in previously untreated mantle cell lymphoma. The study inclu…
Phase: PHASE2 • Sponsor: Weill Medical College of Cornell University • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
Tailored radiation beams aim to boost liver cancer treatment
Disease control OngoingThis trial aims to improve hepatocellular carcinoma (HCC) tumor responses in patients undergoing Y90 radioembolization by using personalized dosimetry as part of treatment planning. Using standard calculations for Y90 doses may not be specific enough for individual patients given…
Phase: NA • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
New drug cocktail shows promise for tough prostate cancer
Disease control CompletedThis is a phase II clinical trial in patients with metastatic castration sensitive prostate cancer. The objective of the study is to determine the efficacy and further define the safety of the treatment combination. This study will evaluate dose levels of carboplatin AUC 4 with c…
Phase: PHASE2 • Sponsor: Masonic Cancer Center, University of Minnesota • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
New combo therapy shows promise for rare blood cancer
Disease control OngoingThe purpose of this multi-center,single arm,phase Ⅱ clinical trail is to determine the safety and efficacy of Sintilimab with P-GemOx (pegaspargase, gemcitabine and oxaliplatin) regimen for newly diagnosed advanced extranodal natural killer/T-cell lymphoma, nasal type (ENKTL)
Phase: PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
New drug cocktail shows promise against tough breast cancer
Disease control OngoingThis research is studying the effect of Antibody-Drug Conjugate Sacituzumab Govitecan in Combination with the Poly (Adenosine Diphosphate \[ADP\]-Ribose) Polymerase (PARP) Inhibitor Talazoparib in Patients with Metastatic Triple-Negative Breast Cancer.
Phase: PHASE1, PHASE2 • Sponsor: Massachusetts General Hospital • Aim: Disease control
Last updated Jul 16, 2026 00:00 UTC
-
New drug combo aims to stop high-risk prostate cancer in its tracks
Disease control CompletedThis is a phase I-II trial to find the safety and activity of adding a new drug (neraparib) to the usual treatment (radiation combined with male hormone deprivation therapy) in lowering the chance of prostate cancer growing or returning. Niraparib is an inhibitor of PARP, an enzy…
Phase: PHASE1, PHASE2 • Sponsor: NRG Oncology • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC
-
New migraine pill aims to stop pain in 2 hours
Symptom relief CompletedAXS-07 is an oral, investigational medicine consisting of MoSEIC meloxicam and rizatriptan, which is being developed for the acute treatment of migraine with or without aura in adults. AXS-07 tablets are formulated to provide an enhanced rate of absorption of meloxicam. This stud…
Phase: PHASE3 • Sponsor: Axsome Therapeutics, Inc. • Aim: Symptom relief
Last updated Jun 27, 2026 09:00 UTC
-
New diabetes pill shows promise for kids in major trial
Disease control CompletedThis study evaluated the safety and efficacy of ertugliflozin (MK-8835) in pediatric participants with T2DM on metformin with/without insulin. The primary hypothesis of the study was that the addition of ertugliflozin reduces hemoglobin A1C (HbA1C) more than the addition of place…
Phase: PHASE3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
Migraine drug aimovig shows promise for medication overuse headache
Disease control CompletedStudy 20170703 is a phase 4, randomized, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy and safety of erenumab against placebo in participants with chronic migraine (CM) who have a history of at least 1 preventive treatment failure and are diagnos…
Phase: PHASE4 • Sponsor: Amgen • Aim: Disease control
Last updated Jun 26, 2026 19:13 UTC
-
Can a 48-Hour drug delay help babies after water breaks early?
Disease control OngoingThe purpose of this study is to assess whether short-term (48 hr) tocolysis reduces perinatal morti-morbidity in cases of PPROM at 22 to 33 completed weeks' gestation.
Phase: PHASE3 • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New vaccine trial aims to stop parasitic worm infection in its tracks
⭐️ VACCINE ⭐️ CompletedThe study will recruit up to 290 healthy adult males and non-pregnant females into a two-part clinical trial of a vaccine to protect against schistosomiasis caused by infection with S. mansoni. Two formulations of the Sm-TSP-2 vaccine will be tested: one using Alhydrogel® only, a…
Phase: PHASE1, PHASE2 • Sponsor: Baylor College of Medicine • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 07:56 UTC